Aline Aparecida Nunes de Souza

Dr. Aline Aparecida Nunes de Souza


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
ASAline Aparecida Nunes de Souza
Aline Aparecida Nunes de Souza
Nagaraju SakkaniNagaraju Sakkani
Nagaraju Sakkani
DGDaryl Guthrie
Daryl Guthrie
RSRajkumar Sahani
Rajkumar Sahani
JSJohn Saathoff
John Saathoff
LJLimei Jin
Limei Jin
(1R,5R)-2,2-Dimethoxybicyclo[3.1.0]hexan-3-one is used in the asymmetric synthesis of lenacapavir. Herein, we report an enantioselective synthesis of this important chiral intermediate from the inexpensive commodity (R)-epichlorohydrin. This synthetic method comprises 6 steps, including a 4-step telescoped bicyclic ketone synthesis, I2-promoted hydroxylation, and an Albright-Goldman oxidation. This sequence affords (1R,5R)-2,2-dimethoxybicyclo[3.1.0]hexan-3-one in an overall 25% isolated yield as an enantiomerically pure compound. The entire process has been successfully demonstrated on a hundred-gram scale.

30 October 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
LJLimei Jin
Limei Jin
DGDaryl Guthrie
Daryl Guthrie
ASAnand Hari Shinde
Anand Hari Shinde
RVRamesh Vediyappan
Ramesh Vediyappan
ASAline Aparecida Nunes de Souza
Aline Aparecida Nunes de Souza
RLRyan Littich
Ryan Littich
This article presents a new three-step process for lenacapavir sodium, a first-in-class HIV capsid inhibitor developed by Gilead Sciences. Lenacapavir has received FDA approval for both treatment of multi-drug resistant HIV (Sunlenca®, 2022) and PrEP (Yeztugo®, 2025). Previous medicinal chemistry synthetic routes relied on separate Pd-catalyzed cou-plings and involved atropisomeric intermediates, resulting in low efficiency. Gilead’s 2024 four-step process improved scalability but retained discrete Pd-catalyzed steps and early-stage incorporation of the costly chiral pyrazole carboxylic acid (Frag C). Our streamlined approach begins with a chiral bromopyridine (Frag A) and features a telescoped Heck-Suzuki coupling and late-stage amidation with Frag C. This marks the first reported one-pot Heck-Suzuki sequence in the synthesis of lenacapavir, minimizing atropisomer handling and simplifying Pd sequestration. The process yields lenaca-pavir API in 50–55% overall yield, with >99.9 wt% purity, and Pd content below 4.2 ppm.

30 April 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
DGDaryl Guthrie
Daryl Guthrie
JSJohn Saathoff
John Saathoff
RSRajkumar Sahani
Rajkumar Sahani
ASAline Aparecida Nunes de Souza
Aline Aparecida Nunes de Souza
DCDaniel Cook
Daniel Cook
LJLimei Jin
Limei Jin
Herein, we describe two practical approaches to synthesize (R)-(+)-1,2-epoxy-5-hexene from inexpensive and readily available raw materials and reagents. The first approach is a two-step sequence, involving an epoxidation with meta-chloroperoxybenzoic acid (mCPBA) and a chiral resolution with (salen)Co(II), producing (R)-(+)-1,2-epoxy-5-hexene in 24-30% of overall yield. The second approach utilizes the readily available (R)-epichlorohydrin as the starting material and features an epoxide ring opening reaction with allylMgCl and the NaOH mediated ring closure reaction. Development of this two-step process affords R-(+)-1,2-epoxy-5-hexene in overall isolated yields of 55-60% with an exceptional purity profile. Both approaches have been successfully demonstrated on 100-200g scales.